CIK 0001420720
- Non-accelerated filer
- Smaller reporting company
iBio, Inc.
Sign in to watch- Ticker
- IBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Jun 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 262797813
- Phone
- +1 302-355-0650
- Business address
- 600 MADISON AVENUE, SUITE 1601, NEW YORK, NY, 10022-1737
- Former names
- iBio, Inc., iBioPharma, Inc., InB:Biotechnologies, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-14 | Stoner Elizabeth Director | Grant or award · Stock Option (right to buy) | +38,000 | 38,000 | ||
| 2026-10-14 | Kropotova Alexandra Director | Grant or award · Stock Option (right to buy) | +38,000 | 38,000 | ||
| 2026-10-14 | Arkowitz David Director | Grant or award · Stock Option (right to buy) | +38,000 | 38,000 | ||
| 2026-10-14 | Clark William D Director | Grant or award · Stock Option (right to buy) | +38,000 | 38,000 | ||
| 2026-10-14 | Parada Antonio Bernardino Guimaraes Director | Grant or award · Stock Option (right to buy) | +38,000 | 38,000 | ||
| 2026-10-14 | Sender Gary Director | Grant or award · Stock Option (right to buy) | +38,000 | 38,000 | ||
| 2026-07-31 | Carr Molly Chief Medical Officer | Grant or award · Stock Option (right to buy) | +430,000 | 430,000 | ||
| 2026-05-18 | Stoner Elizabeth Director | Grant or award · Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2026-03-26 | Banjak Marc Chief Legal Officer | Purchase | +12,500 | $1.64 | $21K | 23,566 |
| 2026-03-26 | Banjak Marc Chief Legal Officer | Purchase | +1,434 | $1.76 | $3K | 25,000 |
| 2026-03-19 | Duran Felipe Chief Financial Officer | Purchase | +24,835 | $2.02 | $50K | 35,974 |
| 2026-03-19 | Brenner Martin See Remarks | Purchase | +12,336 | $2.02 | $25K | 30,652 |
| 2026-01-28 | Banjak Marc Chief Legal Officer | Grant or award · Stock Option (right to buy) | +146,000 | 146,000 | ||
| 2026-01-28 | Duran Felipe Chief Financial Officer | Grant or award · Stock Option (right to buy) | +179,000 | 179,000 | ||
| 2026-01-28 | Brenner Martin See Remarks | Grant or award · Stock Option (right to buy) | +479,000 | 479,000 | ||
| 2025-11-20 | Schimmelpennink Evert B. Director | Grant or award · Stock Option (right to buy) | +13,500 | 13,500 | ||
| 2025-11-20 | Clark William D Director | Grant or award · Stock Option (right to buy) | +13,500 | 13,500 | ||
| 2025-11-20 | Sender Gary Director | Grant or award · Stock Option (right to buy) | +13,500 | 13,500 | ||
| 2025-11-20 | Kropotova Alexandra Director | Grant or award · Stock Option (right to buy) | +13,500 | 13,500 | ||
| 2025-11-20 | Parada Antonio Bernardino Guimaraes Director | Grant or award · Stock Option (right to buy) | +13,500 | 13,500 |
Page 1 of 7 · 126 trades